Related Experiment Videos
Focal segmental glomerulosclerosis in adults
1Renal Unit, Guy's Hospital, King's College, London, UK. jstewart.cameron2@btopenworld.com
Summary
Focal segmental glomerulosclerosis (FSGS) in adults presents diagnostic and treatment challenges. Early corticosteroid treatment helps identify responders, offering a better prognosis, while non-responders often progress to renal failure.
Area of Science:
- Nephrology
- Pathology
- Genetics
Background:
- Focal segmental glomerulosclerosis (FSGS) diagnosis and treatment are complex in adults, often requiring clinical context for interpretation.
- Adult FSGS exhibits diverse etiologies, including idiopathic forms and genetic mutations affecting podocyte proteins.
Purpose of the Study:
- To evaluate the diagnostic challenges and treatment strategies for adult focal segmental glomerulosclerosis (FSGS).
- To determine the utility of corticosteroid therapy in identifying FSGS patient subgroups with differing prognoses.
Main Methods:
- Retrospective analysis of adult nephrotic patients diagnosed with FSGS.
- Assessment of treatment response to a minimum 4-6 month course of corticosteroids.
- Review of existing literature on FSGS management and genetic factors.
Main Results:
- Approximately 20-30% of adult FSGS patients respond to corticosteroids, achieving decreased or lost proteinuria.
- Corticosteroid responders generally have a favorable renal function prognosis, though relapse is possible.
- Non-responders to corticosteroids have a poor prognosis, frequently progressing to end-stage renal disease.
Conclusions:
- Early corticosteroid trial is crucial for stratifying adult FSGS patients.
- Management of non-responsive FSGS remains controversial, lacking robust randomized controlled trial data.
- Further research is needed to establish optimal treatment protocols for heterogeneous adult FSGS populations.